Landmark New Study shows Modified Citrus Pectin Halts Prostate Cancer

Landmark New Study shows Modified Citrus Pectin Halts Prostate Cancer

It’s estimated that close to 250,000 men will be diagnosed with prostate cancer this year in the US. In fact, prostate cancer is the most common cancer in men, aside from non-melanoma skin cancer. In fact, prostate cancer and prostate conditions are in many cases considered a normal part of aging for men. Approximately 70% of men over age 80 show some form of cancer activity in their prostate. While many of these cases are benign or non-threatening, prostate cancer can also become aggressive, fast-moving and deadly. Over 30,000 men die annually of this disease in the US.  

Risks of Hormonal Therapies for Prostate Cancer 

Many conventional as well as natural therapies for prostate cancer rely on hormonal interventions to bring down testosterone levels that can contribute to the cancer growth. Called “androgen deprivation therapy”, this class of hormonal therapies may work initially, but it also comes with high risks of cancer recurrence and treatment resistance. This can happen when the cancer mutates and learns how to grow without relying on hormonal signals, meaning it has become “hormone resistant.” When hormonal therapies stop working, the cancer can become more aggressive and faster growing, and many patients are left with minimal treatment options. Essentially, any time you start interfering with hormones in the body in relation to cancer, the clock starts ticking. Finding non-hormonal therapies that are safe and effective, and don’t interfere with the body’s hormonal activity, is especially critical for many prostate cancer patients, regardless of the severity of their disease.  

Breakthrough Clinical Study on Modified Citrus Pectin in Prostate Cancer  

The urgent need for safe and effective, non-hormonal prostate cancer treatments makes this new clinical study on Modified Citrus Pectin (MCP) so important and groundbreaking. It’s the first published clinical study showing that a natural supplement works against prostate cancer without hormonal mechanisms or interference—thus adding years to patients’ lives.  

Published December 2021 in the journal Nutrients, this multi-center phase II clinical study involved 60 patients with biochemically relapsed prostate cancer, who had been experiencing a rise in their PSA following prostate cancer treatment.  

In the study, patients were given 15 grams of Modified Citrus Pectin daily. Results showed that after 6 months, 78% of participants had either stabilized PSA levels, or increased PSA doubling time (PSADT) with no disease progression shown on imaging scans. PSADT is an important indicator of how fast prostate cancer is progressing, and is often used to measure how well as patient is responding to treatment. The longer the doubling time, the slower the PSA rise, indicating that treatment is working and that the cancer growth has slowed or stopped.  

Study participants continued to show positive benefits with no toxicity or side effects.

78% of study participants showed no prostate cancer progression in response to MCP therapy.1 

  

This is now the third published clinical study highlighting modified citrus pectin as an effective therapy for prostate cancer treatment, with the ability to halt prostate tumor growth and metastasis, stabilize PSA, and increase PSADT. With over 70 published studies total, and more in the pipeline, this form of MCP is earning  recognition among researchers and medical professionals as a safe and effective therapy for prostate cancer, as well as many other cancers.  

Extensive research shows that this modified citrus pectin works against cancer by binding and blocking a master “alarm protein” in the body called galectin-3, which is shown to drive cancer growth and metastasis, as well as cardiovascular disease, organ failure, cytokine storms and sepsis, neurological disease, and many other degenerative conditions. The original and researched form of MCP is known as the most-studied galectin-3 blocker, and the only available agent that can absorb into the bloodstream and block circulating galectin-3, thus haling and reversing cancer and numerous other pro-inflammatory conditions.  

This latest clinical study on MCP in biochemically relapsed prostate cancer makes it clear how MCP can add years to patients’ lives, while supporting increased quality of life through a comprehensive range of safe, natural, non-hormonal benefits and mechanisms that actively promote long-term health and healing. As published data continues to emerge on MCP, patients and health providers can be confident that this is one of the most important daily supplements for protecting and promoting long-term health, and defending against today’s most serious health concerns.  

Source: 

  1. Keizman D, Frenkel M, Peer A, Kushnir I, Rosenbaum E, Sarid D, Leibovitch I, Mano R, Yossepowitch O, Margel D, Wolf I, Geva R, Dresler H, Rouvinov K, Rapoport N, Eliaz I. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. Nutrients. 2021; 13(12):4295.